3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) occupy a central
place in the management of dyslipidemia due to
their documented efficacy in
lowering elevated total cholesterol and low-density lipoprotein
cholesterol (LDL-C) concentrations and reducing
cardiovascular mortality and morbidity